



One Broadway, 14th Floor • Cambridge, MA 02142 • 617-475-1520 • www.invivotherapeutics.com

March 3, 2010

Contacts:

Frank Reynolds 617-475-1518
info@invivotherapeutics.com

For Immediate Release:

InVivo Therapeutics Corporation Featured in March Issue of Inc. Magazine and Publishes 50th Research Article in the Journal of Neuroscience Methods

Cambridge, MA--- In the same week, InVivo Therapeutics Corporation has been recognized for both its business and scientific achievements. In the March 2010 issue of Inc. magazine, an article titled "What Makes Frank Run" profiles CEO Frank Reynolds and his efforts to create and build InVivo Therapeutics Corporation into a global leader in spinal cord injury research. The current feature is a follow-up to the article called "The Future of the Human Body" in the October 2009 issue in which Mr. Reynolds was identified as one of America's top medical entrepreneurs.

Also this week, InVivo's 50th research article was published in the *Journal of Neuroscience Methods*. The publication, titled "Establishing a Model Spinal Cord Injury in the African Green Monkey for the Preclinical Evaluation of Biodegradable Polymer Scaffolds Seeded with Human Neural Stem Cells," identifies the methods used to conduct InVivo's pilot non-human primate study which took place in the spring of 2008. At the time, it was InVivo's most important study to date, and it laid the foundation for subsequent studies which have provided significant results and will be published in the coming months.

Preliminary results from InVivo's large-scale non-human primate study will be released at Bio2010, scheduled to be held in Chicago in May.

*

InVivo Therapeutics Corporation is a Cambridge, MA medical device company focused on combining polymers and stem cells to restore function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of research initiated in the laboratories of Robert Langer, PhD, of the Massachusetts Institute of Technology, Jay Vacanti, MD, of the Massachusetts General and Children's Hospitals in Boston, and Yang Teng, PhD, MD, of Harvard's Brigham and Women's Hospital.